

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 August 2006 (17.08.2006)

PCT

(10) International Publication Number
WO 2006/084910 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/EP2006/050889

(22) International Filing Date:
13 February 2006 (13.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05002936.2 11 February 2005 (11.02.2005) EP
60/652,759 14 February 2005 (14.02.2005) US
05018269.0 23 August 2005 (23.08.2005) EP
60/711,006 24 August 2005 (24.08.2005) US

(71) Applicant (for all designated States except US): **NOLABS AB** [SE/SE]; Kungsgatan 6, S-252 21 Helsingborg (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PETERS, Tor** [SE/CH]; Chalet Marabou Bodemos, CH-1659 Rougemont (CH).



(74) Agent: **KRAHBICHLER, Erik**; Ström & Gulliksson AB, Järnvägsgatan 3, S-252 24 Helsingborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **DEVICE AND METHOD FOR TREATMENT OF DERMATOMYCOSIS, AND IN PARTICULAR ONYCHOMYCOSIS**



(57) Abstract: A device is provided that allows for target treatment of infections, caused by dermatophytes, yeast fungus, and 5 mould fungus, such as onychomycosis and dermatophytosis. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the infected area, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) 10 eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO). Furthermore, a corresponding manufacturing method is provided.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DEVICE AND METHOD FOR TREATMENT OF DERMATOMYCOSIS, AND IN PARTICULAR ONYCHOMYCOSIS**Field of the Invention**

5 This invention pertains in general to the field of treatment of dermatomycosis, and in particular onychomycosis and dermatophytosis. More particularly the invention relates to a device for the therapeutic treatment of dermatomycosis of humans and animals, and in particular
10 onychomycosis and dermatophytosis, and a process for manufacturing of said device, involving the use of nitric oxide (NO).

Background of the Invention

15 Dermatophytes and yeast fungus are the most common reason for superficial fungal infections, and belong to the few infections that are obtained through direct skin-to-skin contact. They are keratinophilic and infect skin, hair, and nails. In some rare cases mould fungus may be the
20 cause of infection (Most often caused by the species *Fusarium*, *Scytalidium*, *Hendersonula* *Toruloidea*, *Scopulariopsis* *Brevicaulis*, *Aspargillus* *Nidulans*, *Acremonium*, *Exophalia* and *Alternaria*). Infections from dermatophytes exist all around the world, but are more
25 common in developing countries, since socioeconomic factors and contact with animals play a big role in the transmittance.

 Superficial fungal infections are mainly caused by the dermatophytes *Trichophyton*, *Epidermophyton* and
30 *Microsporum*. These species are categorised into anthropophilic, i.e. transmits through direct or indirect between humans, zoophilic, i.e. transmits from animals to humans, and geophilic, i.e. transmits from soil.

 Among the yeast funguses *Candida Albicans* is the most
35 pathogenic. Other important *Candida* species, that may cause superficial infections are *C. glabrata*, *C. tropicalis*, *C. krusei*, and *C. parapsilosis*.

Infections from yeast funguses are in most cases caused by *C. Albicans*, and includes vaginitis, stomatitis, dermatitis, paronychia, dermatophytosis (athletes foot) and onychomycosis.

5 Up to this point different types of antimycotics, such as azoles, terbinafine, amorolfine, nystatine, ciclopiroxolamine etc, are available for the local treatment of infections caused by dermatophytes, yeast fungus, and mould fungus. The different types of
10 antimycotics differentiate somewhat in respect of antimicrobial spectrum and pharmacology. These antimycotics are suitable for cutaneous dermatophyte infections, and in some extent for mild forms of onychomycosis.

15 However, these antimycotics do not seldomly cause adverse side effects. Mostly, these adverse side effects are expressed in form of local skin irritation, contact allergic reactions, allergic reactions against preservatives in the antimycotics, drug resistance against
20 the antimycotics etc.

Another way of treating infections from dermatophytes, yeast fungus, and mould fungus is by peroral treatment. Examples of peroral pharmaceuticals are flukanazol, for treatment of dermatological treatment,
25 ketokonazol, for treatment of mucotane candidiasis, itrakonazol, for treatment of infections in nails and skin, and terbinafin, for treatment of infections in nails and skin when local treatment has not given a satisfying result.

30 Peroral treatment also presents a number of adverse side effects, such as negative symptoms in the gastrointestinal tract, headache, oedema, taste disorders etc. In same rare cases the persons treated perorally have died.

It is known that nitric oxide (NO) provides an alternative to conventional therapies, such as antibiotics. Nitric oxide is a highly reactive molecule that is involved in many cell functions. In fact, nitric oxide plays a
5 crucial role in the immune system and is utilized as an effector molecule by macrophages to protect itself against a number of pathogens, such as fungi, viruses, bacteria etc., and general microbial invasion. This improvement of healing is partly caused by NO inhibiting the activation or
10 aggregation of blood platelets, and also by NO causing a reduction of inflammatory processes at the site of an implant.

NO is also known to have an anti-pathogenic, especially an anti-viral, effect, and furthermore NO has an
15 anti-cancerous effect, as it is cytotoxic and cytostatic in therapeutic concentrations, i.e. it has among other effects tumoricidal and bacteriocidal effects. NO has for instance cytotoxic effects on human haematological malignant cells from patients with leukaemia or lymphoma, whereby NO may be
20 used as a chemotherapeutic agent for treating such haematological disorders, even when the cells have become resistant to conventional anti-cancer drugs. This anti-pathogenic and anti-tumour effect of NO is taken advantage of by the present invention, without having adverse effects
25 as for instance many anti-cancer drugs.

However, due to the short half-life of NO, it has hitherto been very hard to treat viral, bacteria, virus, fungi or yeast infections with NO. This is because NO is actually toxic in high concentrations and has negative
30 effects when applied in too large amounts to the body. NO is actually also a vasodilator, and too large amounts of NO introduced into the body will cause a complete collapse of the circulatory system. On the other hand, NO has a very short half-life of fractions of a second up to a few
35 seconds, once it is released. Hence, administration

limitations due to short half-life and toxicity of NO have been limiting factors in the use of NO in the field of anti-pathogenic and anti-cancerous treatment so far.

In recent years research has been directed to
5 polymers with the capability of releasing nitrogen oxide when getting in contact with water. Such polymers are for example polyalkyleneimines, such as L-PEI (Linear PolyEthyleneImine) and B-PEI (Branched PolyEthyleneImine), which polymers have the advantage of being biocompatible.
10 Other example for NO eluting polymers are given in US-5,770,645, wherein polymers derivatized with at least one -NO_x group per 1200 atomic mass unit of the polymer are disclosed, X being one or two. One example is an S-nitrosylated polymer and is prepared by reacting a
15 polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups.

Akron University has developed NO-eluting L-PEI molecule that can be nano-spun onto the surface of medical devices to be permanently implanted in the body, such as
20 implanted grafts, showing significant improvement of the healing process and reduced inflammation when implanting such devices. According to US-6,737,447, a coating for medical devices provides nitric oxide delivery using nanofibers of linear poly(ethylenimine)-diazoniumdiolate.
25 Linear poly(ethylenimine)diazoniumdiolate releases nitric oxide (NO) in a controlled manner to tissues and organs to aid the healing process and to prevent injury to tissues at risk of injury. Electrospun nano-fibers of linear poly(ethylenimine) diazoniumdiolate deliver therapeutic
30 levels of NO to the tissues surrounding a medical device while minimizing the alteration of the properties of the device. A nanofiber coating, because of the small size and large surface area per unit mass of the nanofibers, provides a much larger surface area per unit mass while
35 minimizing changes in other properties of the device.

US 2002/0082221 discloses a nitric oxide releasing S-nitrosylated, N-nitrosylated, and/or O-nitrosylated lipid and administration methods thereof. This lipid may be integrated and provided within a polymer matrix. Thus, it is not the polymer that elutes NO in US 2002/0082221, but the lipid. Therefore, the system according to US 2002/0082221 is in need of a nitric oxide eluting lipid. Nothing is mentioned of regulating and/or controlling the elution of NO.

US 2002/0136750 discloses a dosage form for the treatment of bacterial, virus, or fungal conditions, said dosage form comprising an acidifying agent and a source of nitrate ions or a precursor thereof, wherein said acidifying agent and nitrate ions are kept separate in carriers. These carriers, comprising acidifying agent and nitrate ions, respectively, are then mixed to induce elution of nitric oxide. Nothing is mentioned of regulating and/or controlling the elution of NO.

EP 1 300 424 discloses extremely hydrophobic NO releasing polymers. These polymers are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. Since the polymer according to EP 1 300 424 is extremely hydrophobic, and "highly resistant to penetration by water and insoluble therein", page 9, line 30, it is unclear how the NO is released. Nothing is mentioned of regulating and/or controlling the elution of NO.

US 5,814,666 discloses compositions capable of releasing nitric oxide for the treatment of microorganism-related diseases. The compositions comprise one or more nitric oxide generators, preferably encapsulated in vesicles, such as liposomes. The active moiety of the compositions in US 5,814,666 is N_2O_2^- . This group may be bound to a polymer. However, nothing is mentioned of regulating and/or controlling the elution of NO.

US 2004/0043068 discloses a medical device coated with a coating, comprising a polyurea network, which can be associated with and release nitric oxide, in one embodiment of US 2004/0043068. US 2004/0043068 does not mention dermal
5 treatment but only vascular diseases and Raynard's disease (see page 9, paragraph 86). Nothing is mentioned of regulating and/or controlling the elution of NO.

WO 2005/003032 discloses zeolites containing releasably adsorbed nitric oxide. Zeolites are not
10 polymers. Nothing is mentioned of regulating and/or controlling the elution of NO.

WO 2004/012874 discloses a nitric oxide releasing medical device. The device comprises a substrate to which an amine-functionalized silane residue can be bound, such
15 as a metallic surface, and nitric oxide bound to the substrate through NO-releasing nucleophiles, which are bonded to said amine-functionalized silane residue. Nothing is mentioned of regulating and/or controlling the elution of NO.

20 US 6,737,447 discloses a coating for medical devices, which coating provides NO delivery by using nanofibres of L-PEI. Nothing is mentioned of regulating and/or controlling the elution of NO or treatment of dermatomycosis.

25 Furthermore, the disclosures are silent concerning an improvement of present technology in respect of treatment of disorders caused by dermatophytes, yeast fungus, and mould fungus, and the anti pathogenic potential of nitric oxide.

30 Hence, an improved, or more advantageous, device for the treatment and/or prevention of infection, caused by dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis. It is desired that said device does not develop resistance against the active
35 pharmaceutical substance, and which does not cause local

skin irritation or contact allergic reactions, negative symptoms in the gastrointestinal tract, headache, oedema, taste disorders etc, would be advantageous, and in particular a device allowing for target prevention and treatment of infections, such as onychomycosis and dermatophytosis, would be advantageous.

Summary of the Invention

Accordingly, the present invention preferably seeks to mitigate, alleviate or eliminate one or more of the above-identified deficiencies in the art and disadvantages singly or in any combination and solves, among others, at least the problems mentioned above, by providing a device, a manufacturing method for the latter and a use of nitric oxide according to the appended patent claims.

According to one aspect of the invention, a device is provided that allows for target treatment of infections, caused by dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the infected area, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area.

According to another aspect of the invention, a manufacturing process for such a device is provided, wherein the process is a process for forming a device that allows for target treatment of infections, caused by dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis. The process comprises selecting a plurality of nitric oxide eluting polymeric particles, such as nano fibres, fibres, nano particles, or microspheres, and deploying said nitric oxide eluting particles in a condom/sheath or tape/coating to be comprised in said device. Alternatively the NO eluting particles are admixed to an ointment, cream, gel or foam.

The present invention has at least the advantage over the prior art that it provides target exposure of an infected area to NO, whereby a very effective anti-dermatophyte, anti-yeast fungus, and/or anti-mould fungus
5 therapy is achievable.

Brief Description of the Drawings

These and other aspects, features and advantages of which the invention is capable of will be apparent and
10 elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which

Fig. 1 is a schematic illustration of a condom/sheath according to the invention,

15 Fig. 2 is a schematic illustration of a tape or coating according to the invention,

Fig. 3 is a schematic illustration of a sock according to the invention, and

Fig. 4 is a graph illustrating different elutions of
20 nitric oxide from two different mixtures of nitric oxide eluting polymers.

Description of Embodiments

The following description focuses on embodiments of
25 the present invention applicable to a device, in form of a condom/sheath, which allows for target treatment of infections caused by dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis.

With regard to nitric oxide (nitrogen monoxide, NO),
30 its physiological and pharmacological roles have attracted much attention and thus have been studied. NO is synthesized from arginine as the substrate by nitric oxide synthase (NOS). NOS is classified into a constitutive

enzyme, cNOS, which is present even in the normal state of a living body and an inducible enzyme, iNOS, which is produced in a large amount in response to a certain stimulus. It is known that, as compared with the
5 concentration of NO produced by cNOS, the concentration of NO produced by iNOS is 2 to 3 orders higher, and that iNOS produces an extremely large amount of NO.

In the case of the generation of a large amount of NO as in the case of the production by iNOS, it is known that
10 NO reacts with active oxygen to attack exogenous microorganisms and cancer cells, but also to cause inflammation and tissue injury. On the other hand, in the case of the generation of a small amount of NO as in the case of the production by cNOS, it is considered that NO
15 takes charge of various protective actions for a living body through cyclic GMP (cGMP), such as vasodilator action, improvement of the blood circulation, antiplatelet-aggregating action, antibacterial action, anticancer action, acceleration of the absorption at the digestive
20 tract, renal function regulation, neurotransmitting action, erection (reproduction), learning, appetite, and the like. Heretofore, inhibitors of the enzymatic activity of NOS have been examined for the purpose of preventing inflammation and tissue injury, which are considered to be
25 attributable to NO generated in a large amount in a living body. However, the promotion of the enzymatic activity (or expressed amount) of NOS (in particular, cNOS) has not been examined for the purpose of exhibiting various protective actions for a living body by promoting the enzymatic
30 activity of NOS and producing NO appropriately.

In recent years research has been directed to polymers with the capability of releasing nitrogen oxide when getting in contact with water. Such polymers are for example polyalkyleneimines, such as L-PEI (Linear
35 PolyEthyleneImine) and B-PEI (Branched PolyEthyleneImine),

which polymers have the advantage of being biocompatible. Another advantage is that NO is released without any secondary products that could lead to undesired side effects.

5 The polymers may be manufactured by electro spinning, gas spinning, air spinning, wet spinning, dry spinning, melt spinning, or gel spinning. Electro spinning is a process by which a dissolved polymer is charged. At a characteristic voltage a fine jet of polymer releases from
10 the surface in response to the tensile forces generated by interaction by an applied electric field with the electrical charge carried by the jet. This process produces a bundle of polymer fibres, such as nano-fibres. This jet of polymer fibres may be directed to a surface to be
15 treated.

 Furthermore, US 6,382,526, US 6,520,425, and US 6,695,992 disclose processes and apparatuses for the production of such polymeric fibres. These techniques are generally based on gas stream spinning, also known within
20 the fiber forming industry as air spinning, of liquids and/or solutions capable of forming fibers.

 Other example for NO eluting polymers are given in US-5,770,645, wherein polymers derivatized with at least one -NOX group per 1200 atomic mass unit of the polymer are
25 disclosed, X being one or two. One example is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups.

 Akron University has developed NO-eluting L-PEI
30 molecule that can be nano-spun onto the surface of permanently implanted medical devices, such as implanted grafts, showing significant improvement of the healing process and reduced inflammation when implanting such devices. According to US-6,737,447, a coating for medical
35 devices provides nitric oxide delivery using nanofibers of

linear poly(ethylenimine)-diazoniumdiolate. Linear poly(ethylenimine)diazoniumdiolate releases nitric oxide (NO) in a controlled manner.

However, the meaning of "controlled" in the context of US 6,737,447 is only directed to the fact that nitric oxide is eluted from the coating during a period of time, i.e. that the nitric oxide not is eluted all in once. Therefore, the interpretation of "controlled" in respect of US 6,737,447 is different from the meaning of "regulating" in the present invention. "Regulate or control", according to the present invention is intended to be interpreted as the possibility to vary the elution of nitric oxide to thereby achieve different elution profiles.

A polymer comprising an O-nitrosylated group is also a possible nitric oxide eluting polymer. Thus, in one embodiment of the present invention, the nitric oxide eluting polymer comprises diazoniumdiolate groups, S-nitrosylated and O-nitrosylated groups, or any combinations thereof.

In still another embodiment of the present invention said nitric oxide eluting polymer is a poly(alkyleneimine)diazoniumdiolate, such as L-PEI-NO (linear poly(ethyleneimine)diazoniumdiolate), where said nitric oxide eluting polymer is loaded with nitric oxide through the diazoniumdiolate groups and arranged to release nitric oxide at a treatment site.

Some other examples of a suitable nitric oxide eluting polymer are selected from the group comprising amino cellulose, amino dextrans, chitosan, aminated chitosan, polyethyleneimine, PEI-cellulose, polypropyleneimine, polybutyleneimine, polyurethane, poly(buthanediol spermate), poly(iminocarbonate), polypeptide, Carboxy Methyl Cellulose (CMC), polystyrene, poly(vinyl chloride), and polydimethylsiloxane, or any combinations of these, and these mentioned polymers grafted

to an inert backbone, such as a polysaccharide backbone or cellulosic backbone.

In still another embodiment of the present invention the nitric oxide eluting polymer may be a O-derivatized
5 NONOate. This kind of polymer often needs an enzymatic reaction to release nitric oxide.

Other ways of describing polymers, which may be suitable as nitric oxide eluting polymer, is polymers comprising secondary amine groups ($=N-H$), such as L-PEI, or
10 have a secondary amine ($=N-H$) as a pendant, such as aminocellulose.

In an embodiment of the invention, according to Fig. 1, the device is in form of a latex or rubber condom/sheath 10, 12, said condom/sheath being covered on the inside with
15 nano-filament of any of the NO-eluting polymers according to above, such as polyalkyleneimines, such as L-PEI (Linear PolyEthyleneImine) and B-PEI (Branched PolyEthyleneImine), which polymers have the advantage of being biocompatible, after the release of nitrogen oxide.

20 In another embodiment of the present invention the condom/sheath is covered on the inside with nano-filament of L-PEI.

This condom/sheath may be in any suitable size, such as a suitable size for rolling said condom/sheath over the
25 toe or finger, on which toe or finger the nail to be treated is located. These sizes may for example vary from small, medium, and large sized condoms/sheaths for a little finger, ring finger, middle finger, fore finger, or thumb, or small, medium, and large sized condoms/sheaths for a
30 little toe, the three middle toes, or big toe. The condom/sheath according to the invention may even have a size suitable for covering a foot, such as a sock 30, according to Fig. 3, or a foot-condom/sheath, or other specific part of the body, to be able to treat
35 dermatomycosis on larger areas. According to an embodiment,

the condoms/sheaths are coated with NO eluting nano fibres. According to another embodiment the condoms/sheaths are made of or comprise nanofilaments, e.g. made by electro or gas jet spinning. Other manufacturing methods, such as wet
5 spinning, dry spinning, melt spinning, and gel spinning, are also within the scope of the present invention.

According to a further embodiment the condoms/sheaths comprises microspheres eluting NO in use. Preferably the three aforementioned embodiments employ L-PEI material
10 loaded with NO. Activation on NO release may be done by e.g. foot sweat, water sprayed onto the condoms/sheaths immediately prior to use, or a water bag configured for releasing water upon activation, e.g. by pushing onto the bag thus bursting (see below).

15 When the NO-eluting condom/sheath according to certain embodiments of the present invention is treated with or gets in contact with the moisture, in form of secreted sweat, the NO-eluting condom/sheath starts to release NO to the area to be treated. Alternatively the
20 device is moistured or wettened immediately prior to application or use for controlling or activating the NO release.

In another embodiment of the present invention a condom/sheath is covered on the inside with NO-eluting
25 nano-particles, or micro-spheres. These nano-particles, or micro-spheres, may be formed from the NO-eluting polymers comprised in the present invention. They may also be encapsulated in any suitable material, such as polyethylene, polypropylene, polyacrylonitrile,
30 polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein
35 based polymers, gelatine, biodegradable polymers, cotton,

and latex, or any combinations of these. When the nano-particles, or micro-spheres, according to this embodiment, gets in contact with the secreted moisture, in form of sweat, on the inside of the condom/sheath, they start to
5 elute NO on the area to be treated.

In the context of the present invention the term "encapsulating" is intended to be interpreted as fixating the nitric oxide eluting polymer in a three dimensional matrix such as a foam, a film, a nonwoven mat of nano-
10 fibers or fibers, or other materials with the capability to fixate the NO eluting polymer, or enclosing the nitric oxide eluting polymer in any suitable material.

In yet another embodiment of the present invention the condom/sheath contains a small proton donor bag or
15 sealed proton donor sponge. This proton donor bag or sealed proton donor sponge is used to activate the elution of NO from the NO-eluting nano-particles, or micro-spheres. This proton donor bag or sealed proton donor sponge may be located in the tip of the condom/sheath according to the
20 invention. Persons that not easily sweat may be helped by the use of this embodiment.

In another embodiment of the present invention a nitric oxide eluting polymer is provided, and/or combined, with microencapsulated proton donor (which will be
25 described in further detail below), such as water or water containing liquid.

This may for example be done by first manufacture micro capsules, containing proton donor, such as water or water containing liquid, in a state of the art manner.
30 These micro capsules are then applied on the NO eluting polymer. The application of the micro capsules on the NO eluting polymer may for example be done by gluing, such as pattern gluing, or instead spinning the NO eluting polymer onto said micro capsules. In this way a device or a system,
35 comprising NO eluting polymer and micro encapsulated water

or water containing liquid is manufactured. When the device or system is applied on the target area the device or system is compressed or squeezed. Said compression or squeezing results in breakage of the micro capsules. The NO
5 eluting polymer is thus exposed to said water or water containing liquid, and the elution of NO from the NO eluting polymer is initiated on the target area. In other embodiments of the present invention the liquid inside the micro capsules is released by heating or shearing the micro
10 capsules until the micro capsules are ruptured.

In still another embodiment the micro capsules, are formed into a film, tape, or sheath. Thereafter, a film, tape, or sheath of an NO eluting polymer is glued onto the film, tape, or sheath of micro capsules. Preferably the
15 film, tape, or sheath of the NO eluting polymer is glued onto the film, tape, or sheath of the micro capsules, in patterned way. The obtained pattern includes spaces where there is no glue, in which spaces the proton donor will be transported to the NO eluting polymer once the micro
20 capsules are broken from compression or squeezing. When the proton donor gets in contact with the NO eluting polymer the elution of NO starts. Thus, the combination of film, tape, or sheath of micro capsules, and NO eluting polymer may be applied on a target area. Thereafter the combination
25 is compressed or squeezed, which results in that the target area is exposed to NO.

In yet another embodiment the NO eluting polymer is spun directly onto the film, tape, or sheath of micro capsules, containing proton donor. The combination of film,
30 tape, or sheath of micro capsules, and spun NO eluting polymer may be applied on a target area. Thereafter the combination is compressed or squeezed, which results in that the target area is exposed to NO.

In still another embodiment of the present invention
35 the device or system is provided with an activation

indicator. This activation indicator indicates when the micro capsules are satisfyingly broken, hence when the NO eluting polymer is subjected to enough proton donor to elute an efficient amount of NO. This activation indicator
5 may for example be obtained by colouring the proton donor that is trapped inside the micro capsules. When the micro capsules are broken the coloured proton donor escapes the microcapsules and the colour gets visualised while efficiently wetting the NO eluting polymer. Another way of
10 obtaining an activation indicator is to choose to manufacture the micro capsules in a material, or choose a wall thickness of said micro particles, that creates a sound when the micro capsules break. It is also possible to admix a scent in the proton donor, contained in the micro
15 capsules. This results in that the user of the device or system may smell the scent when the proton donor escapes from the micro capsules after breakage thereof.

In another embodiment a substance that changes color when it comes in contact with water can be incorporated in
20 the device. Thus when the water capsules or water bag breaks the material changes color, thereby indicating that the material is activated.

In another embodiment of the present invention the device or system only allows NO-elution in one direction.
25 In this kind of embodiment one side of the device according to the invention has low permeability, or substantially no permeability, to nitric oxide. This may be accomplished by applying a material on one side of the device according to the invention that is not permeable to NO. Such materials
30 may be chosen from the group comprising common plastics, such as fluoropolymers, polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol,
35 polystyrene, polyethers, polycarbonates, polyamides,

polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. This embodiment is also easy to manufacture as the NO
5 eluting polymer, e.g. L-PEI (or nitric oxide eluting polymer and carrier material, which will be explained in more detail below) may be electro or gas-jet spun onto the surface of the device according to the invention of e.g. the mentioned plastics, latex, or cotton.

10 In still another embodiment the device is provided with one membrane, which is permeable to nitric oxide, on a first side of the device, and another membrane, which has low permeability or substantially no permeability to nitric oxide, on a second side of said device. This embodiment
15 provides the possibility to direct the elution to said first of the device, while the elution of nitric oxide is substantially prevented from said second side. Thereby, a greater amount of nitric oxide will reach the intended area to be treated.

20 The activation of the nitric oxide eluting polymer may be accomplished by contacting said polymer with a suitable proton donor (as mentioned above). In one embodiment the proton donor may be selected from the group comprising water, body fluids (blood, lymph, bile, etc.),
25 alcohols (methanol, ethanol, propanols, butanols, pentanols, hexanols, phenols, naphtols, polyols, etc.), aqueous acidic buffers (phosphates, succinates, carbonates, acetates, formats, propionates, butyrates, fatty acids, amino acids, etc.), or any combinations of these.

30 By adding a surfactant in the proton donor one can facilitate the wetting of the device. The surfactant lowers the surface tension and the activating fluid is easily transported throughout the device.

In still another embodiment the device may be
35 manufactured in the form of a polyurethane, or

polyethylene, tape or coating 20, according to Fig. 2. This polyurethane tape or coating may easily be wrapped around the toe or finger, at which toe or finger the nail to be treated is located. At least the side facing the toe, or
5 nail, may be covered with NO-eluting nano-particles, or micro-spheres, or nano-filament of NO-eluting L-PEI. When these particles or filaments get in contact with the moisture, in form of sweat, on the inside of the tape or coating, the elution of NO starts.

10 In another embodiment of the device according to the present invention, it is in form of a patch/pad, which patch/pad is suitable to be applied between the toes or fingers, and onto other areas that are difficult to get at.

Certain embodiments of the invention directly
15 implement treatment by releasing NO to the toe/finger-nail. NO diffuses through the nail and treatment is performed even under the nail. Conventionally, if an infection, or onychomycosis or dermatomycosis, is present under such a nail, the nail is surgically removed and then therapeutic
20 treatment is started. Hence, these embodiments save a patient from a lot of pain and other complications that may occur at during and after these toe removal operations.

Of course, in other embodiments of the invention, the patch/pad or tape/coating may be manufactured by any other
25 suitable material, such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides,
30 polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. The NO-eluting polymer may be integrated in, spun together with, or spun on top of, any of these materials in all of
35 the embodiments of the present invention.

In another embodiment these nano-particles, or microspheres, may be integrated in a soluble film that disintegrates on the inside of the condom/sheath or tape/coating, in order to elute NO at the area of interest
5 when the soluble film gets in contact with the moisture, in form of sweat or from the water bag or sealed water sponge, on the area to be treated.

When placed on an area to be treated the device provides prevention and treatment of infections, caused by
10 dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis.

In another embodiment of the present invention the device only allows NO-elution in one direction. In this kind of embodiment one side of the condom/sheath or
15 tape/coating is non-permeable to NO. This may be accomplished by applying a material on one side of the condom/sheath or tape/coating that is not permeable to NO. Such materials may be chosen from the group comprising common plastics, such as polyethylene, polypropylene,
20 polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose
25 (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. This embodiment is also easy to manufacture as the NO eluting polymer, e.g. L-PEI nano fibres may be electro or gas-jet spun onto the surface of a condom sheath of e.g.
30 the mentioned plastics, latex, or cotton. Other manufacturing methods are also within the scope of the present invention, such as wet spinning, dry spinning, melt spinning, and gel spinning. In the case of a condom it may be rolled up, or a sheath may be turned outside in after
35 manufacturing to protect the NO eluting polymer during

packaging, transport and prior to use from external influences, being e.g. mechanical (abrasion of the polymer), chemical (moisture deactivating the device prior to use) etc.

5 In yet another embodiment of the present invention the NO-eluting device is acting as a booster for drug eluting patches, e.g. pharmaceuticals, vitamins, nicotine, nitroglycerin etc. This embodiment presents a device with the advantage of combining two therapeutic treatments, of
10 significant value, in one treatment. Hence, a synergetic effect may be achieved by such devices when NO that is eluted from the device. NO has a vasodilatory effect on the region where the device having the combination compound actuates. Vasodilated tissue is more susceptible to certain
15 medications and thus more easily treated by the medical preparations and still NO has in addition to that the anti-inflammatory, anti-bacterial etc. effect. Hence, an unexpected surprisingly effective treatment is provided.

 In still another embodiment the nitric oxide eluting
20 polymer, such as powder, nano-particles or micro-spheres, can be incorporated in foam. The foam may have an open cell structure, which facilitates the transport of the proton donor to the nitric oxide eluting polymer. The foam can be of any suitable polymer such as polyurethane, polystyrene,
25 polyester, polyvinylchloride, polyolefins, or latex.

 In another embodiment the device is in form of a cream, a gel or a combination of the two. Since the nitric oxide eluting polymer is activated by proton donors the nitric oxide eluting polymer has to be separate from the
30 proton donor until one wants to initiate the elution of nitric oxide, i.e. use the device. One way to accomplish this is to have a syringe with two separate containers. In one container you have a proton donor-based gel and in the other a non proton donor-based gel, comprising the nitric
35 oxide eluting polymer. Upon using the device the two gels

are squeezed from the syringe and mixed together, the proton donor in the first gel comes in contact with the nitric oxide eluting polymer in the second gel and the elution of nitric oxide starts.. The elution of NO may then
5 be initiated by applying a water soaked patch on said gel or foam. This embodiment has the advantage of being able to penetrate pockets and corners in the skin for closer elution of NO on the area to be treated.

The device elutes nitric oxide (NO) from said eluting
10 polymer in a therapeutic dose, such as between 0.001 to 5000 ppm, such as 0.01 to 3000 ppm, such as 0.1 to 1000 ppm, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 15 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 ppm. The concentration may vary widely depending on where the
20 concentration is measured. If the concentration is measured close to the actual NO eluting polymer the concentration may be as high as thousands of ppm, while the concentration inside the tissue in this case often is considerably lower, such as between 1 to 1000 ppm.

25 In the embodiments of the present invention it may be suitable to control or regulate the time span of NO release from the device according to the invention. This may be accomplished by integrating other polymers or materials in said device. These polymers or materials may be chosen from
30 any suitable material or polymer, such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates,
35 polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl

Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these.

Three important factors in controlling and regulating the elution of nitric oxide from a nitric oxide eluting polymer are how quickly a proton donor comes in contact with the nitric oxide releasing polymer, such as a diazoliiumdiolate group, the acidity of the environment surrounding the nitric oxide eluting polymer, and the temperature of the environment surrounding the nitric oxide releasing polymer (higher temperature promotes elution of nitric oxide).

In one embodiment of the present invention a nitric oxide eluting polymer, such as L-PEI-NO, is mixed with a carrier polymer to slow down or prolong the elution of nitric oxide. Also, in another embodiment, the nitric oxide eluting polymer may be mixed with more than one carrier polymer, whereby the elution or release may be tailor made to fit specific needs. Such a need may for example be a low elution during a first period of time, when the environment of the nitric oxide eluting polymer is hydrophobic, and a faster elution during a second period of time, when the environment of the nitric oxide eluting polymer has been altered to be more hydrophilic. This may for example be accomplished by using biodegradable polymers, whereby a low elution during a first period of time is obtained, after which, when the hydrophobic polymer has been dissolved, the hydrophilic polymer provides a higher elution of nitric oxide. Thus, a more hydrophobic carrier polymer will give a slower elution of nitric oxide, since the activating proton donor, such as water or body fluid, will penetrate the carrier polymer slower. On the other hand, a hydrophilic polymer acts the opposite way. One example of an hydrophilic polymer is polyethylene oxide, and one example of an hydrophobic polymer is polystyrene. These carrier

polymers may be mixed with the nitric oxide eluting polymer and then electrospun to suitable fibers. The skilled person in the art knows which other polymers may be used for similar purposes. Fig. 4 illustrates two elution profiles
5 (NO concentration vs. time) for two different polymer mixtures; a nitric oxide eluting polymer mixed with a hydrophilic carrier polymer in an acidic environment (A), and a nitric oxide eluting polymer mixed with a hydrophobic carrier polymer in a neutral environment (B).

10 In one embodiment this carrier polymer is substituted by another material with hydrophobic or hydrophilic properties. Therefore, the term "carrier material" in the present context should be interpreted to include carrier polymers and other materials with hydrophilic or
15 hydrophobic properties.

In another embodiment of the present invention the elution of nitric oxide from a nitric oxide eluting polymer, such as L-PEI-NO, is influenced by the presence of protons. This means that a more acidic environment provides
20 a quicker elution of nitric oxide. By activating the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material, with an acidic fluid, such as an ascorbic acid solution, the elution of nitric oxide may be accelerated.

25 The carrier polymers and carrier materials mentioned in above may affect other characteristics than the regulation of nitric oxide elution. An example of such characteristic is mechanical strength.

In respect of the carrier polymers or carrier
30 materials, the NO-eluting polymer may be integrated in, spun together with, or spun on top of, any of these materials in all of the embodiments of the present invention. This spinning includes electrospinning, air spinning, wet spinning, dry spinning, melt spinning, and
35 gel spinning. In this way, one may manufacture fibers of a

polymer mixture, comprising a nitric oxide eluting polymer and a carrier polymer, or a carrier material, with predefined nitric oxide eluting characteristics. These characteristics may be tailor made for different elution profiles in different applications.

The NO-eluting polymers in the devices may be combined with silver, such as hydroactivated silver. The integration of silver in the devices gives the healing process an extra boost. Preferably the silver is releasable from the devices in the form of silver ions. The integration of silver in the device may present several advantages. One example of such an advantage is that the silver may keep the device in itself free from bacteria or viruses, while the nitric oxide eluting polymer elutes the therapeutic dosage of nitric oxide to the target site.

The nitric oxide eluting polymer may comprise a secondary amine, either in the backbone or as a pendant, as described previously. This will make a good nitric oxide eluting polymer. The secondary amine should have a strong negative charge to be easy to load with nitric oxide. If there is a ligand close to the secondary amine, such as on a neighbour atom, such as a carbon atom, to the nitrogen atom, with higher electronegativity than nitrogen (N), it is very difficult to load the polymer with nitric oxide. On the other hand, if there is a electropositive ligand close to the secondary amine, such as on a neighbour atom, such as a carbon atom, to the nitrogen atom, the electronegativity of the amine will increase and thereby increase the possibility to load the nitric oxide elution polymer with nitric oxide.

In an embodiment of the present invention the nitric oxide polymer may be stabilized with a salt. Since the nitric oxide eluting group, such as a diazeniumdiolate group, usually is negative, a positive counter ion, such as a cation, may be used to stabilize the nitric oxide eluting

group. This cation may for example be selected from the group comprising any cation from group 1 or group 2 in the periodic table, such as Na^+ , K^+ , Li^+ , Be^{2+} , Ca^{2+} , Mg^{2+} , Ba^{2+} , and/or Sr^{2+} . Different salts of the same nitric oxide
5 eluting polymer have different properties. In this way a suitable salt (or cation) may be selected for different purposes. Examples of cationic stabilized polymers are L-PEI-NO-Na, i.e. L-PEI diazeniumdiolate stabilized with sodium, and L-PEI-NO-Ca, i.e. L-PEI diazeniumdiolate
10 stabilized with calcium.

Another embodiment of the present invention comprises mixing the nitric oxide eluting polymer, or a mixture of the nitric oxide eluting polymer and a carrier material, with an absorbent agent. This embodiment provides the
15 advantage of an accelerated elution of nitric oxide since the polymer, or polymer mixture, via the absorbent agent, may take up the activating fluid, such as water or body fluid, much faster. In one example 80 % (w/w) absorbent agent is mixed with the nitric oxide eluting polymer, or
20 mixture of nitric oxide eluting polymer and carrier material, and in another embodiment 10 to 50 % (w/w) absorbent agent is mixed with the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material.

25 Since the elution of nitric oxide is activated by a proton donor, such as water, it may be an advantage to keep the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material, in contact with said proton donor. If an indication requires an elution of
30 nitric oxide during a prolonged period of time, a system is advantageous, which presents the possibility to keep the proton donor in contact with the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material. Therefore, in still another embodiment of
35 the present invention, the elution of nitric oxide may be

regulated by adding an absorbent agent. The absorbent agent absorbs the proton donor, such as water, and keeps the proton donor in close contact with the nitric oxide eluting polymer during prolonged periods of time. Said absorbent
5 agent may be selected from the group comprising polyacrylates, polyethylene oxide, carboxymethylcellulose, and microcrystalline cellulose, cotton, and starch. This absorbent agent may also be used as a filling agent. In this case said filling agent may give the nitric oxide
10 eluting polymer, or mixture of said nitric oxide eluting polymer and a carrier material, a desired texture.

The device may be manufactured by, for example electro spinning of L-PEI or other polymers comprising L-PEI or being arranged in combination with L-PEI. L-PEI is
15 the charged at a characteristic voltage, and a fine jet of L-PEI releases as a bundle of L-PEI polymer fibres. This jet of polymer fibres may be directed to a surface to be treated. The surface to be treated may for example be any suitable material in respect of a device. The electro spun
20 fibres of L-PEI then attach on said material and form a coating/layer of L-PEI on the device according to the invention.

It is of course possible to electro spin the other NO-eluting polymers, according to above, on the device
25 according to the invention while still being inside the scope of the present invention.

In one embodiment the NO-eluting polymers according to the present invention are electro spun in such way that pure NO-eluting polymer fibres may be obtained.

30 It is also within the scope of the present invention to electro spin a NO-eluting polymer together with other suitable polymer/polymers.

Gas stream spinning, air spinning, wet spinning, dry spinning, melt spinning, and gel spinning, of said NO-

eluting polymers onto the device is also within the scope of the present invention.

The manufacturing process presents the advantages of large contact surface of the NO-eluting polymer fibres with the area to be treated, effective use of NO-eluting polymer, and a cost effective way of producing the device.

Hereinafter, some potential uses of the present invention are described:

A method of therapeutically treating an infection, including onychomycosis and dermatophytosis by means of a device that comprises a nitric oxide (NO) eluting polymer configured for eluting a therapeutic dosage of nitrogen oxide (NO) when used for said treatment, comprising exposing said treatment site of said infection in or on a body to said nitric oxide when said polymer in use elutes nitrogen oxide (NO) by eluting a therapeutic dose of nitric oxide from said nitric oxide eluting polymer to said treatment site.

The method according to the above, wherein said site of said infection is an extremity of a body, and wherein said method comprises applying a condom/sheath, sock, patch/pad, and tape/coating to said extremity for said exposure.

Use of nitric oxide (NO) in a therapeutic dose for therapeutically treating onychomycosis and/or dermatophytosis.

The invention may be implemented in any suitable form. The elements and components of the embodiments according to the invention may be physically, functionally, and logically implemented in any suitable way. Indeed, the functionality may be implemented in a single unit, in a plurality of units, or as part of other functional units.

Although the present invention has been described above with reference to specific embodiments, it is not intended to be limited to the specific form set forth

herein. Rather, the invention is limited only by the accompanying claims and, other embodiments than the specific above are equally possible within the scope of these appended claims.

5 In the claims, the term "comprises/comprising" does not exclude the presence of other elements or steps. Furthermore, although individually listed, a plurality of means, elements or method steps may be implemented. Additionally, although individual features may be included
10 in different claims, these may possibly advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or advantageous. In addition, singular references do not
15 etc do not preclude a plurality. Reference signs in the claims are provided merely as a clarifying example and shall not be construed as limiting the scope of the claims in any way.

20

CLAIMS

1. A device configured to therapeutically treat infections, including onychomycosis and dermatophytosis,
5 c h a r a c t e r i z e d i n t h a t
said device comprises a nitric oxide (NO) eluting polymer configured to elute a therapeutic dosage of nitrogen oxide (NO) when used for said treatment, and
wherein said nitric oxide (NO) eluting polymer is
10 integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO),
wherein said device is configured to expose a treatment site of said infection, in or on a body, to said
15 nitric oxide when said polymer in use elutes nitrogen oxide (NO).

2. Device according to claim 1, wherein said nitric oxide (NO) eluting polymer comprises diazeniumdiolate
20 groups, S-nitrosylated groups, and O-nitrosylated groups, or any combination these.

3. Device according to claim 1 or 2, wherein said nitric oxide (NO) eluting polymer is L-PEI (linear
25 polyethyleneimine), loaded with nitric oxide (NO) through said diazeniumdiolate groups, S-nitrosylated groups, or O-nitrosylated groups, or any combination these, arranged for release of the nitric oxide (NO) at said target site in or on a body for treatment of or prevention infections,
30 including onychomycosis and dermatophytosis thereby.

4. Device according to claim 1, wherein said nitric oxide eluting polymer is selected from the group comprising amino cellulose, amino dextrans, chitosan, aminated
35 chitosan, polyethyleneimine, PEI-cellulose, polypropyleneimine, polybutyleneimine, polyurethane,

poly(buthanediol spermate), poly(iminocarbonate), polypeptide, Carboxy Methyl Cellulose (CMC), polystyrene, poly(vinyl chloride), and polydimethylsiloxane, or any combinations of these, and these mentioned polymers grafted
5 to an inert backbone, such as a polysaccharide backbone or cellulosic backbone.

5. Device according to claim 1, has a form selected from the group consisting of a condom/sheath, a sock, a
10 patch/pad, and a tape/coating, adapted to be applied on or at said treatment site of said infection in or on a body for treatment of infections, including onychomycosis and dermatophytosis.

15 6. Device according to claim 5, wherein said condom/sheath, sock, patch/pad, and tape/coating is manufactured of polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates,
20 polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these,
25 and said condom/sheath, sock, patch/pad, or tape/coating, includes said nitric oxide (NO) eluting polymer configured to, in use, elute said nitric oxide (NO) to said treatment site of said infection in or on a body for treatment of said infection.

30

7. Device according to any of claims 1 to 6, including a proton donor bag, sealed proton donor sponge or proton donor micro capsules, configured for releasing said proton donor therefrom when activated to said device, and

wherein said polymer is activateable to elute nitric oxide (NO) upon contact with said proton donor.

8. Device according to claim 1, wherein said device
5 is partly disintegrable when subjected to a proton donor.

9. Device according to claim 7 or 8, wherein said
proton donor is selected from the group comprising water,
blood, lymph, bile, methanol, ethanol, propanols,
10 butanols, pentanols, hexanols, phenols, naphtols, polyols,
phosphates, succinates, carbonates, acetates, formats,
propionates, butyrates, fatty acids, amino acids, or any
combinations of these.

15 10. Device according to claim 9, said proton donor
having added a surfactant thereto, said surfactant in use
facilitating wettening of the device.

11. Device according to claim 1, wherein said polymer
20 comprises silver, configured for therapeutical treatment of
said site of said infection in or on the body.

12. Device according to claim 1, wherein said polymer
is comprised in the device in form of nano-particles or
25 micro-spheres.

13. Device according to claim 12, wherein said nano-
particles, or micro-spheres, are integrated in a gel,
cream, foam, or hydrogel, or combinations thereof.

30 14. Device according to claim 12 or 13, wherein said
nano-particles, or micro-spheres, are integrated with,
preferably encapsulated in, a material, selected from the
group comprising polyethylene, polypropylene,
35 polyacrylonitrile, polyurethane, polyvinylacetates,

polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose
5 (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these.

15. Device according to claim 1, wherein said carrier material is selected from the group comprising
10 polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins,
15 poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these.

16. Device according to claim 1, comprising an
20 absorbent agent, configured to absorb a proton donor, and to thereby keep said proton donor in close contact with the nitric oxide eluting polymer during prolonged periods of time.

25 17. Device according to claim 16, wherein said absorbent agent is selected from the group comprising polyacrylates, polyethylene oxide, carboxymethylcellulose, and microcrystalline cellulose, cotton, and starch.

30 18. Device according to claim 1, wherein said nitric oxide eluting polymer is stabilized by a cation.

19. Device according to claim 18, wherein said cation is selected from the group comprising Na^+ , K^+ , Li^+ , Be^{2+} ,
35 Ca^{2+} , Mg^{2+} , Ba^{2+} , and Sr^{2+} , or any combinations thereof.

20. Device according to claim 1, wherein said nitric oxide eluting polymer comprises a secondary amine, either in the backbone or as a pendant.

5

21. Device according to claim 20, wherein a positive ligand is located close to said secondary amine.

22. Device according to claim 20, wherein said
10 electropositive ligand is located on a neighbour carbon atom to the nitrogen atom in said secondary amine in the backbone.

23. Device according to any preceding claim, wherein
15 said device is configured to therapeutically treat onychomycosis or dermatophytosis.

24. A manufacturing process for a device configured to therapeutically treat infections, including
20 onychomycosis and dermatophytosis, according to claim 1, comprising:

selecting a nitric oxide (NO) eluting polymer configured to elute a therapeutic dosage of nitric oxide (NO) when used for said therapeutic treatment of
25 infections,

selecting a carrier material, which carrier material is configured to regulate and control the elution of said therapeutic dosage of nitric oxide (NO),

incorporating the NO-eluting polymer with said
30 carrier material into an nitric oxide (NO) eluting material, such that said carrier material, in use of said device, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO), and

35 deploying said nitric oxide eluting material into a suitable form, or as a coating onto a carrier, to form at

least a part of said device, such that said device is configured to expose a therapeutic target site to said nitric oxide when said NO-eluting polymer in use elutes nitric oxide (NO).

5

25. The manufacturing process according to claim 24, wherein said deploying comprises electro spinning, air spinning, gas spinning, wet spinning, dry spinning, melt spinning, or gel spinning of NO-eluting polymer.

10

26. The manufacturing process according to claim 24 or 25, wherein said selecting said nitric oxide (NO) eluting polymer comprises selecting a plurality of nitric oxide (NO) eluting polymeric particles, preferably nano fibres, nano particles or micro spheres.

15

27. The manufacturing process according to claim 24 or 25, wherein said incorporating said NO-eluting polymer with said carrier material comprises integrating said NO-eluting polymer in said carrier material, spinning said NO-eluting polymer together with said carrier material, or spinning said NO-eluting polymer on top of said carrier material, in order to predefine nitric oxide eluting characteristics of said device.

20

28. The manufacturing process according to claim 24, further comprising integrating silver in said device.

29. The manufacturing process according to claim 24, further comprising microencapsulating proton donor in micro capsules, and

30

applying the micro capsules to said nitric oxide (NO) eluting material.

30. The manufacturing process according to claim 29, wherein said applying comprises pattern gluing, or spinning the NO eluting material onto said micro capsules.

5 31. The manufacturing process according to claim 29, comprising forming the micro capsules into a first film, tape, or sheath,
 forming a second film, tape, or sheath of said NO eluting material, and
10 gluing the first film, tape, or sheath of micro capsules to said second film, tape, or sheath of said NO eluting material.

 32. The manufacturing process according to claim 31, wherein said gluing comprises patterned gluing, such that a pattern is obtained including glue free spaces.

 33. The manufacturing process according to claim 29, comprising forming the micro capsules into a first film, tape, or sheath, and directly spinning the NO eluting material onto the film, tape, or sheath of micro capsules, containing a proton donor.

 34. The manufacturing process according to claim 29, comprising providing an activation indicator configured to indicate when the micro capsules are broken such that the NO eluting material is subjected to said proton donor to elute NO.

30 35. The manufacturing process according to claim 34, wherein said providing an activation indicator comprises providing a coloring agent inside the micro capsules.

 36. The manufacturing process according to claim 34, wherein said providing an activation indicator comprises

selecting a material for the micro capsules, or choosing a wall thickness of said micro capsules, that creates a sound when the micro capsules break.

5 37. The manufacturing process according to claim 34, wherein said providing an activation indicator comprises admixing a scent material into the micro capsules.

 38. The manufacturing process according to claim 34,
10 wherein said providing an activation indicator comprises providing a substance that changes color when it comes in contact with the proton donor.

 39. Use of a nitric oxide (NO) eluting polymer for
15 the manufacture of a device for the treatment of infections, including onychomycosis and dermatophytosis wherein

 nitric oxide is loaded to said device so said device elutes nitric oxide (NO) from said eluting polymer in a
20 therapeutic dose when used at a site of infection in or on a body.

 40. Use according to claim 39, wherein said therapeutic dose is between 0.001 to 5000 ppm, such as 0.01
25 to 3000 ppm, such as 0.1 to 1000 ppm, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 30 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 ppm.

 41. A method of therapeutically treating an
35 infection, including onychomycosis and dermatophytosis by

means of a device that comprises a nitric oxide (NO) eluting polymer configured for eluting a therapeutic dosage of nitrogen oxide (NO) when used for said treatment, comprising

- 5 exposing said treatment site of said infection in or on a body to said nitric oxide when said polymer in use elutes nitrogen oxide (NO) by eluting a therapeutic dose of nitric oxide from said nitric oxide eluting polymer to said treatment site.

10

42. The method according to claim 41, wherein said site of said infection is an extremity of a body, and wherein said method comprises applying a condom/sheath, sock, patch/pad, and tape/coating to said extremity for
15 said exposure.

20

43. Use of nitric oxide (NO) in a therapeutic dose for therapeutically treating and/or preventing onychomycosis and/or dermatophytosis.

44. Use according to claim 43, comprising therapeutically treating onychomycosis and/or dermatophytosis under a finger- or toe-nail.

- 25 45. Use of nitric oxide (NO) in a medicament for therapeutically treating and/or preventing onychomycosis and/or dermatophytosis at a treatment side of a body.

30

1/4




Fig. 1




Fig. 2




Fig. 3




Fig. 4